| BackgroundOvarian carcinoma is the third commonest tumor in gynecologic maligncies.Because of its latent and atypical symptoms, lacking of effective early diagnosis andtherapeutic methods, ovarian carcinoma always remains the first dead reason ingynecologic malignant tumors.The treatment of ovarian carcinoma is a general therapy including surgery basedand combining with chemotheraPy or radiotherapy, but the effect seems very poor so far.It is urgently necessary to find a new way matching surgery and chemotherapy to delaythe reoccurance and improve the survival. With the development of the molecu1arbiology, immunol0gy, and oncology the biological therapy and gene theraPy for ovariancarcinoma are becoming to realize.Immune theraPy is an important part of biological therapy for ovarian carcinoma, ofthose, the cytokine theraPy is regarded as a hOt spot, which mainly include iflterferon-y(lFN-y) and interleukin-2 (IL-2), and has gotten some achievements. In recent years,the antitUmor effeet of interleukin-7 has been noticed by many scholars. Interleukin-7 isa kinds of cytokines produced by matrix cell in bone marrow lt can not only stimulate ofpre B cells mature, but also accelerate the mature T cells proliferation, and enhance Tcells function and promote reactivity of 1ymphokines. One of the focuses on antitumorresearch of IL-7 is the IL-7 gene transfer into the tumor cells. This IL-7 gene therapymay avoid toxic adverse effects of cytokine therapy in vivo by using cytokinecontinuously and largely because of its short biologica1 halftime. Up to noW fewstudies repofted about using lL-7 to inhibit proliferation of tumor cells directly in vitro,but it was certain that IL-7 had some antitumor activity in vivo. Some research indicatedthat the immunogenicity of the tumor cells was enhanced when transferred with IL-7gene. Experiments based on the murine mode1s also proved that the vaccine modified byIL-7 gene induced the vehicle's antitumor immunity of and decrease the tumorigenesisof tumor cells.As we knoW few studies about the relationship between the ovarian carcinoma andIL-7 were reported. Based on the former research in our laboratory we consider thattissue or cell of ovarian carcinoma does not or rarely secrete IL-7. Considering no reportabout the therapy of transgenic tumor vaccine of IL-7 against ovarian carcinoma, wedecided to investigate the IL-7 gene therapy by using the SKOV3-IL-7 cell line whichwas transferred with IL-7 gene and stablly expressed IL-7 in vivo.A suitable animal model for the research of ovarian carcinoma is needed. Severecombined immune deficient mice (SCID mice) make the research of human's malignanttumors stride fOrward. The main characters of SCID mice are severe defection of T Blymphocyte's function. Immunoglobin can not be detected in serum. The number oflymphocytes in peripheral blood is decreased significant1y. TherefOre SCID micebecome a good carrier system for xenografting. Following different kinds of humantumors in SCID mice successively established, SCID mice also become an ideal modelfor transplaniation of human tumors. Now the scholars focus on how to simulate thestatus of human carcinoma in immune enviroment. In l988, a stable humanized modelwas firstly established by Moiser. Up tO noW Hu-SCID mice is considered as the mostsuitable model for the research of immune therapy on tumors, because of its simulatingthe human's natural status, In that it can take the place of the human body to researchgene theraPy and immune theraPy It makes great effect in screening antitumor drugs andselecting therapeutic methods.Although the intraperitoneal transplantation mode1 of human ovarian carcinoma hasbeen established in abroad successively, there were few researches about ovariancarcinoma in SCID mice in domestic, only subcotaneous transplant8tion model of humanovarian carcinoma was reported. This model is hard to reflect the characteristics ofp... |
PDF Full Text Request